Johnson & Johnson (JNJ) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Johnson & Johnson (JNJ) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 32.6% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +69.9% for JNJ. Johnson & Johnson is the larger company by market cap ($651.11 billion vs $130.58 billion), about 5.0 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs +6.0%).
On valuation, Johnson & Johnson trades at a lower forward P/E (23.3x vs 25.9x for Vertex Pharmaceuticals). Johnson & Johnson pays a dividend yielding 1.95%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 28.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JNJ | VRTX |
|---|---|---|
| Share price | $270.47 | $515.02 |
| Market cap | $651.11B | $130.58B |
| 1-day change | +1.25% | -1.08% |
| YTD return | +30.69% | +13.60% |
| 1-year return | +32.65% | +20.68% |
| 5-year return | +69.89% | +180.53% |
| P/E ratio (TTM) | 41.04 | 33.14 |
| Forward P/E | 23.29 | 25.86 |
| EPS (TTM) | $6.59 | $15.54 |
| Dividend yield | 1.95% | 0.00% |
| Annual dividend | $5.28 | $0.00 |
| Revenue (latest FY) | $94.19B | $12.00B |
| Revenue growth (YoY) | +6.05% | +8.90% |
| Net income (latest FY) | $26.80B | $3.95B |
| Gross margin | 67.88% | 86.24% |
| Operating margin | — | 34.77% |
| Net margin | 28.46% | 32.94% |
| 52-week high | $290.25 | $568.67 |
| 52-week low | $199.91 | $412.27 |
| Distance from 52-week high | -6.81% | -9.43% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.31% | +15.60% |
| Average volume | 7.29M | 1.25M |
| Shares outstanding | 2.41B | 253.54M |
| Employees | 138,200 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Johnson & Johnson is about 5.0 times larger than Vertex Pharmaceuticals by market value ($651.11B vs $130.58B).
- JNJ has outperformed VRTX by 12.0 percentage points over the past year.
- Johnson & Johnson offers a meaningfully higher dividend yield (1.95% vs 0.00%).
About Johnson & Johnson
JNJ stock →Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Health Care · Biotechnology: Pharmaceutical Preparations · 138,200 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
JNJ vs VRTX FAQ
Which is bigger, Johnson & Johnson or Vertex Pharmaceuticals?
Johnson & Johnson (JNJ) is larger, with a market capitalization of $651.11B compared with $130.58B for Vertex Pharmaceuticals (VRTX).
Which stock has performed better over the past year, JNJ or VRTX?
JNJ returned +32.65% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, JNJ or VRTX?
VRTX has the lower trailing P/E at 33.1, versus 41.0 for JNJ. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Johnson & Johnson or Vertex Pharmaceuticals?
Johnson & Johnson pays a dividend yielding 1.95%, while Vertex Pharmaceuticals does not currently pay a regular dividend.
Are Johnson & Johnson and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.